BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Onchilles Pharma Inc readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Onchilles Pharma Inc's drugs run\
 , from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07339176-2630@assetmemo.bio
DTSTAMP:20261121T010131Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:N17350: Phase 1/2 readout est. (NCT07339176)
DESCRIPTION:N17350\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Intrat
 umoral N17350 in Advanced Solid Tumors\nEstimated primary completion: July
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/n17350#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07339176
URL:https://assetmemo.bio/drug/n17350#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
